BioInvent will continue to focus its efforts on its fully owned drug development candidates BI-505 in stage II for Multiple Myeloma and BI-1206, where a First-in-Human research in non-Hodgkin's Lymphoma is expected to start late 2014/early 2015. ‘We have become pleased to give priority to our fully owned portfolio and to realise value from our stake in the ADC-1013 project. We are also pleased that we have been in a position to contribute to the joint task with Alligator Bioscience’, says BioInvent's CEO Michael Oredsson..After the conclusion of the commenting treatment, the preliminary survey was revised and the ultimate report delivered to the contracting agency, the Federal government Joint Committee, at the beginning of February 2009. The documentation of the written comments shall be published in another document simultaneously with the ultimate report. An overview is supplied by The executive summary of the background, methods, and additional results of the ultimate report.
Achieving meaningful use of inpatient EHR is normally top priority of hospital executives: Survey According to a study of U.S. Medical center executives released today by CSC , steps to meet meaningful use requirements were already a priority for hospitals before the final rules to establish an incentive program for electronic health information were announced by america Department of Health insurance and Human Services on July 12.